TLR7 and neoplasm: Accordingly, studies in CT26 tumor-bearing mice indicated that IT TransCon TLR7/8 Agonist treatment mediated potent single agent anti-tumor activity in a dose-dependent manner, with a favorable tolerability profile at all dose levels tested, as indicated by lack of treatment-related weight loss or change in body condition score in treated animals.